EU says Novartis MS drug needs heart monitoring
LONDON/ZURICH (Reuters) – The European Medicines Agency advised doctors to continuously monitor patients for six hours after giving them a first dose of Novartis AG's multiple sclerosis drug Gilenya, casting a shadow over the potential blockbu…
View full post on Yahoo! Health News
drug, Heart, monitoring, needs, Novartis, Says